Budesonide/Formoterol Fumarate Powder for Inhalation Combined with Compound Methoxyphenamine Clinical Efficacy Analysis of Subacute Cough in SARS-COV-2 Infection
Objective To retrospectively analyze the clinical efficacy of Xinbikedubao[budes-onide/formoterol fumarate powder for inhalation(Ⅰ)=320 μg/9.0 μg]combined with compound me-thoxyphenamine(ASME)in the treatment of subacute cough after acute respiratory syndrome coronavirus-2(SARS-COV-2)infection.Methods 220 patients with subacute cough of SARS-COV-2(Omicron BA.5.2,BF.7 infection)diagnosed from December 2022 to June 2023 were collected,and divided into observation group and control group,110 cases in each group.In the observation group,the patients were treated with Xinbikedubao(1 inhalation/time,2 times/day)and ASME(2 capsules/time,3 times/day);in the control group,the patients were treated with three combinations of cough suppressants,keto-tifen and montelukast sodium.The cough evaluation test(CET)was used to observe and record the cough relief on the 3rd,5th and 7th days after treatment,and fractional exhaled nitric oxide(FeNO)was detected and evaluated for efficacy.Results Cough CET score and FeNO value detection of patients on the 3rd,5th and 7th days after treatment decreased compared with before.In the observation group,there were 86 cases of clinical control,11 cases of significant effect,9 cases of effective and 4 cases of inef-fective,with a total effective rate of 96％;in the control group,there were 68 cases of clinical control,17 cases of significant effect,13 cases of effective and 12 cases of ineffective,with a total effective rate of 89％.The difference in the total effective rate of the two groups was statistically significant when com-pared with each other(P＜0.05).Conclusion The combination of Xinbikedubao and ASME for the treatment of subacute cough in SARS-COV-2(Omicron BA.5.2,BF.7 infection)significantly improved patients'cough symptoms.
budesonide/formoterol fumarate powder for inhalationcompound methoxyphena-minecombined treatmentacute respiratory syndrome coronavirus-2coughcough evaluation test
万方数据
维普
